Siolta Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Siolta Therapeutics, Inc. - overview
Established
2016
Location
San Carlos, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2016 by CEO Nikole Kimes, Siolta Therapeutics, Inc. operates as a developer of microbiome therapeutics combined with bacteria, fungi, protozoa, and viruses that lives inside the human body to treat and prevent inflammatory diseases. In March 2024, Siolta Therapeutics, Inc. raised USD 12 million in Series C funding co-led by Capital Management and Khosla Ventures, with participation from Seventure, Global Brain, Time Ventures, and National Institute of Allergy and Infectious Diseases.
Siolta Therapeutics, Inc. developed live biotherapeutics and molecular diagnostic tools to target the core drivers of diseases particularly within the maternal-infant axis. It leverages advanced microbial science, clinical data, and bioinformatics to create targeted therapies. The company’s products are designed to reestablish a healthy gut microbiome using naturally occurring bacteria and are focused to prevent and treat a variety of diseases, including atopic conditions and other disorders associated with microbiome dysbiosis.
The company plans to use the funding from March 2024 to support the further clinical development of Siolta’s lead product, STMC-103H, a defined-consortia Live Biotherapeutic Product (LBP) focused on preventing the onset of atopic diseases in newborns.
Current Investors
Khosla Ventures, Seventure Partners, Global Brain
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.sioltatherapeutics.com
Verticals
Manufacturing
Company Stage
Series C
Total Amount Raised
Subscriber access only
Siolta Therapeutics, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.